ArticleBMC cancer2026
Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-programmed death 1 (PD-1) antibodies, a type of immune checkpoint inhibitor (ICI), have enhanced survival rates in non-small cell lung cancer (NSCLC). While some patients with NSCLC have pre-existing interstitial lung disease (ILD), data on the long-term safety and effectiveness of anti-PD-1 antibodies for this group are still unclear.
methodsWe examined patients with advanced NSCLC who experienced recurrence after surgery or radiotherapy and received anti-PD-1 antibody monotherapy at Aichi Cancer Center Hospital from December 2015 to December 2018. The study assessed the connection between progression-free survival (PFS) and overall survival (OS) with respect to pre-existing ILD, and also investigated how ICI-induced pneumonitis impacted OS.
resultsAmong the 200 patients, 35 (17.5%) had pre-existing ILD. There were no significant differences in OS between the ILD and non-ILD groups, with 5-year OS rates of 21.1% and 24.8% respectively (HR = 0.99; 95% CI, 0.66–1.48; p = 0.956). ICI-induced pneumonitis was more common in the pre-existing ILD group (40.0% vs. 12.1%, P < 0.001). A 90-day landmark analysis showed no statistically significant difference in OS between patients with and without ICI-induced pneumonitis.
conclusionAlthough the occurrence of ICI-induced pneumonitis was common, patients with NSCLC having pre-existing ILD exhibited comparable long-term survival rates to those without ILD. The potential risks and benefits should be thoroughly assessed when contemplating ICIs for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.